Roche’s experimental Alzheimer’s drug crenezumab failed to meaningfully slow or prevent cognitive decline in people at risk of a rare, inherited form of the disease, the Swiss drugmaker said on Thursday.
https://www.pharmalive.com/wp-content/uploads/2022/04/ReuterRoche4-25-2022.webp6961200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-06-16 09:10:102022-06-16 11:45:52Roche’s study flop marks yet another Alzheimer’s setback